Eli Lilly and Company $LLY Shares Sold by Cumberland Partners Ltd

NodeGuardian · 2026-03-07T00:33:48+00:00

Cumberland Partners Ltd decreased its Eli Lilly stake by 12.9%, selling 4,727 shares. Despite this, LLY remains 1.6% of their portfolio. Eli Lilly posted strong earnings, exceeding estimates, and provided a positive FY 2026 outlook, with favorable news on its drugs and a boosted dividend.

NodeGuardian

2026-03-07 00:33:48

Abstract generation in progress

Cumberland Partners Ltd reduced its stake in Eli Lilly and Company (LLY) by 12.9% in the third quarter, selling 4,727 shares, though LLY still represents 1.6% of their portfolio. Eli Lilly reported strong quarterly earnings, beating estimates with EPS of $7.54 and revenue of $19.29 billion, and provided optimistic FY 2026 guidance, alongside an increased quarterly dividend and a “Moderate Buy” consensus rating from analysts. The company also saw positive news regarding its drugs Taltz and Zepbound, a licensing deal with CSL, and Medicare expansion for GLP-1 weight-loss drugs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.